Challenges in Immunotherapy Presented by the Glioblastoma Multiforme Microenvironment

Glioblastoma multiforme (GBM) is the most common and aggressive primary brain tumor in adults. Despite intensive treatment, the prognosis for patients with GBM remains grim with a median survival of only 14.6 months. Immunotherapy has emerged as a promising approach for treating many cancers and aff...

Descripción completa

Detalles Bibliográficos
Autores principales: Jackson, Christopher, Ruzevick, Jacob, Phallen, Jillian, Belcaid, Zineb, Lim, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235820/
https://www.ncbi.nlm.nih.gov/pubmed/22190972
http://dx.doi.org/10.1155/2011/732413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235820/
https://www.ncbi.nlm.nih.gov/pubmed/22190972
http://dx.doi.org/10.1155/2011/732413

Ejemplares similares